{
    "doi": "https://doi.org/10.1182/blood.V108.11.5339.5339",
    "article_title": "Compared Molecular Monitoring of BCR-ABL Transcripts in Peripheral Blood and Bone Marrow Samples in CML Patients after Allogeneic Hematopoiteic Stem Cell Transplant. ",
    "article_date": "November 16, 2006",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "Background. Molecular monitoring of the BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) using quantitative real-time polymerase chain reaction (QRT-PCR) provides important information about the leukemia cell mass and the response to therapy. After allogeneic hematopoietic stem cell transplants (HSCT) patients with persistently positive levels of BCR-ABL transcript have a molecular relapse and some of these patients progress to develop a cytogenetic or hematologic relapse. Objectives. To test whether molecular detection of BCR-ABL transcripts is comparable using peripheral blood (PB) and bone marrow (BM) aspirate samples after allogeneic HSCT. Patients and Methods. BCR-ABL transcripts were monitored the interval of time 2003 \u2013 2005 in 118 patients who received an allogeneic HSCT in chronic or advanced disease phase. BCR-ABL transcripts were evaluated concomitantly in 200 blood samples and 200 marrow samples (total 400 determinations) using real time PCR (QRT-PCR) assay to analyze BCR-ABL gene rearrangement (p210 b2a2 and b3a2). A complete molecular response (CMR) both for PB and BM we defined has undetectable levels of p210 and Major molecular response (MMR) was defined when p210/ABL ratios where <0.02%. Results. 135 double BM+PB determinations (67%) proved BCR-ABL negative ; 61 double determinations (31%) were classified as \u201cpersistently positive\u201d both in peripheral blood and in blood marrow; 4 determinations (2%) were discordant. Therefore 196/200 BCR-ABL determinations in peripheral blood and bone marrow (98 %) were concordant. Conclusions. This study shows that BCR-ABL QRT PCR monitoring of CML patients after allogeneic HSCT with peripheral blood cells is concordant with bone marrow cells in 98% of cases, and thus may be used to monitor the disease. This may be relevant for patients, especially when quality of life issues are discussed together with the need for post-transplant monitoring.",
    "topics": [
        "bcr-abl tyrosine kinase",
        "bone marrow specimen",
        "hematopoietic stem cell transplantation",
        "allogeneic hematopoietic stem cell transplant",
        "polymerase chain reaction",
        "cardiac mri",
        "leukemia",
        "leukemia, myelocytic, chronic",
        "measles-mumps-rubella vaccine",
        "quantitative real-time polymerase chain reaction"
    ],
    "author_names": [
        "Alida Dominietto, MD",
        "Gabriella Cirmena",
        "Anna Garuti",
        "Anna Maria Raiola, MD",
        "Adalberto Ibatici, MD",
        "Maria Teresa van Lint, MD",
        "Francesco Frassoni, MD",
        "Andrea Bacigalupo, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Alida Dominietto, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Gabriella Cirmena",
            "author_affiliations": [
                "Dipartimento di Medicina Interna, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Garuti",
            "author_affiliations": [
                "Dipartimento di Medicina Interna, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Maria Raiola, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Adalberto Ibatici, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Teresa van Lint, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Frassoni, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Bacigalupo, MD",
            "author_affiliations": [
                "Divisione di Ematologia 2, Ospedale San Martino, Genova, Italy"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-02T06:36:32",
    "is_scraped": "1"
}